ROSS DAVID MERKIN, MD

Plain English
This study looked at two patients with a rare type of cancer in the lacrimal sac, which is the area around the tear ducts, and both patients were positive for certain types of HPV (HPV16 and HPV33). Researchers monitored the levels of circulating tumor DNA (ctDNA) from these patients before, during, and after their treatment with chemotherapy and radiation, and found that using ctDNA tracking can effectively help detect and monitor the cancer's response to treatment. This finding is important because it supports the use of ctDNA as a non-invasive way to keep an eye on treatment success, which could guide future care for patients with this type of cancer. Who this helps: Patients with lacrimal sac squamous cell carcinoma and their doctors.

Plain English
Researchers developed an artificial intelligence tool that predicts whether head and neck cancer patients will have cancer return or die within the next five years after surgery, using patient information like age, tumor characteristics, and blood test results collected over time. The AI tool was 70-80% accurate at making these predictions across different time points, and worked especially well for a specific type of throat cancer caused by HPV (93% accurate at one year). This matters because doctors can now identify patients at high risk of recurrence or death earlier, allowing them to adjust treatment plans—either intensifying care for those most likely to relapse or reducing harsh treatments for those with better odds.

Plain English
Researchers examined a blood test that detects tumor DNA in patients with a specific type of head and neck cancer that doesn't involve HPV. They found that when the test showed positive results after treatment, it indicated a higher chance of cancer recurrence and lower survival rates. This finding is important because it suggests that this blood test could help doctors identify patients at greater risk after treatment, potentially leading to more tailored monitoring and care.

Plain English
Researchers studied a blood test that detects tiny amounts of tumor DNA in patients with a specific type of throat cancer that is not linked to HPV. They found that when this DNA was present, patients were more likely to experience a recurrence of their cancer and had a shorter survival time. This finding is important because it suggests that this blood test could help doctors predict outcomes and make better treatment decisions for patients with this type of cancer.

Plain English
This study looked at how people with recurrent or metastatic head and neck cancer do depending on whether their cancer is linked to human papillomavirus (HPV). It found that patients with HPV-positive cancer lived longer than those with HPV-negative cancer, with an average overall survival of 20.7 months versus 12.2 months for the first treatment, and 11.1 months versus 8.3 months for later treatments. This matters because understanding these differences can help doctors provide better treatment and care for their patients, and improve how new therapies are developed. Who this helps: Patients with head and neck cancer, their doctors, and researchers.

Plain English
This study looked at how different settings on a new laser device, the Quanta Litho 150, affect its ability to break down stones in a lab setting. The researchers found that the best results for breaking down material were achieved using the "virtual basket" setting at 2 Joules and 15 Hertz and the "vapor tunnel" setting at 2.5 Joules and 12 Hertz. Specifically, these settings reached the highest efficiency of stone removal at 1.15 mg per minute. Who this helps: This information benefits doctors performing laser treatments for kidney stones and similar conditions.

Plain English
This study looked at patients with a serious heart condition called immune checkpoint inhibitor-associated myocarditis (ICIM) to understand what factors might help them survive longer. Among the 35 patients studied, 25.7% survived less than 30 days, while the rest were divided into two groups who survived up to 365 days or longer. Key findings showed that those who started treatment sooner and had better heart function by day 8 after treatment were more likely to survive longer. Who this helps: This information benefits doctors and healthcare providers by helping them identify patients who may need more aggressive treatment.

Plain English
This study looks at how immune checkpoint inhibitors, which are drugs used to treat cancer, can sometimes cause harmful side effects known as immune-related adverse events (irAEs). Researchers found that current treatments for these side effects, mainly high doses of corticosteroids, may not always be effective, and they discuss using drugs that block specific cytokines—proteins involved in immune responses—to treat these adverse events. For instance, using inhibitors targeting certain cytokine pathways might offer better treatment options for patients experiencing issues such as inflammation of the intestines or skin reactions. Who this helps: This helps cancer patients who are undergoing treatment and may experience immune-related side effects.

Plain English
This study looked at how effective a cancer treatment called cetuximab is for patients with recurrent or metastatic head and neck cancer who have already received a different type of therapy called immune checkpoint inhibitors (ICIs). Among 70 patients, cetuximab worked for about 21.4% of them, with those receiving it alongside chemotherapy seeing a better response (27.7%) and longer treatment duration. The results highlight that patients with virus-independent tumors and those who don’t smoke experienced better outcomes, which is important for guiding treatment decisions. Who this helps: This helps doctors in choosing the best treatment plans for their patients with head and neck cancer.

Plain English
This study examined how certain structures in the tumor called tertiary lymphoid structures (TLS) can help predict which patients with head and neck cancer will respond to a specific type of immunotherapy known as immune checkpoint blockade (ICB). Researchers looked at tumor samples from 20 patients, finding that those who responded to treatment had more B cells present and better survival rates when TLS were located close to the tumor. The study also showed that measuring TLS density could predict treatment response with 80% accuracy, suggesting it may be a better indicator than the currently used marker. Who this helps: This helps patients with recurrent head and neck cancer by improving treatment prediction and outcomes.

Plain English
Researchers studied how changes in blood samples containing tumor DNA could help predict how well patients with advanced head and neck cancer respond to treatment and how long they might live. They found that when patients had lower levels of this tumor DNA during treatment, they were more likely to respond positively and have better survival rates. This is important because using this DNA information could help doctors make better treatment decisions, potentially improving outcomes for patients.

Plain English
Researchers studied patients with a severe type of head and neck cancer that often comes back or spreads. They found that monitoring a specific marker in the blood, known as circulating tumor DNA (ctDNA), can help predict how well patients will respond to treatment and how long they might live. This is important because it offers a new way to tailor treatments to individual patients, potentially improving their chances of survival and minimizing side effects from ineffective therapies.

Plain English
Adenoid cystic carcinoma (ACC) is a deadly cancer that doesn't respond well to current treatments because tumors hide from the immune system—they have very low levels of a protein called HLA class I that the immune system needs to recognize and attack cancer cells. Researchers discovered that treating ACC tumors with immune-activating drugs called STING agonists can turn this protein back on, and when they tested this approach in one patient combined with an existing immunotherapy drug, the tumor shrank by 70%. This finding suggests that turning HLA class I back on with STING agonists could finally make immunotherapy work for ACC patients.

Plain English
Researchers developed a new blood test using advanced DNA sequencing to detect HPV-associated head and neck cancers early, before symptoms appear, and compared it to three other blood-based detection methods. The new sequencing test detected cancer 98.7% of the time it was present and correctly identified healthy people 98.7% of the time—significantly better than existing blood tests. This breakthrough matters because HPV-related head and neck cancers are becoming more common, yet doctors currently have no way to catch them early when treatment is most effective.

Plain English
Researchers developed a highly sensitive blood test that detects tiny amounts of HPV cancer DNA left in patients after surgery for HPV-related head and neck cancer. They found that patients whose blood still contained this cancer DNA had much worse outcomes—only 60% stayed cancer-free for 2 years compared to 100% of patients with no detectable DNA—and this blood test was better at predicting who would relapse than current methods doctors use. The test could also spot cancer coming back up to 17 months before it shows up on scans or causes symptoms, giving doctors an early warning system to decide whether patients need additional treatment like chemotherapy or radiation.

Plain English
This study looked at a specific type of thyroid cancer called differentiated high-grade thyroid carcinoma (DHGTC) across 40 cases from six medical centers. Researchers found that the average age of patients with this type of cancer was 64 years, and the tumors were generally large, averaging about 4.9 cm. They discovered that 68% of the cases had high-risk genetic mutations, and over 97% of the samples tested had concerning cytologic features that could indicate a severe cancer type, which is important for guiding patient treatment and management. Who this helps: This research benefits patients diagnosed with thyroid cancer and their doctors by improving understanding of how to identify and treat aggressive forms of the disease.

Plain English
This study looked at how certain immune cells in head and neck cancer tumors can predict whether patients will respond well to a treatment called immune checkpoint blockade (ICB). The researchers found that patients who responded to ICB had a higher amount of B lymphocytes (CD20+ cells) in their tumors compared to those who did not respond (22% vs. lower levels). Additionally, certain structures called Tertiary Lymphoid Structures (TLS) near the tumors were linked to better survival rates, with a 4% higher chance of overall survival among patients with these structures. Who this helps: This research helps patients with head and neck cancer by identifying better predictors of treatment response.

Plain English
This study looked at how to treat lung cancer patients whose cancer has spread to the brain but who don’t have specific genetic changes that could be targeted by newer treatments. It compared starting treatment with either radiation therapy or immunotherapy. The researchers found that while immunotherapy can work for some patients, careful selection is crucial—patients should not have severe symptoms, should have small brain lesions, and should show high levels of a specific protein (PD-L1) to qualify for this approach. This matters because it could lead to better treatment strategies and reduce the need for immediate radiation for some patients. Who this helps: Patients with lung cancer that has spread to the brain.

Plain English
This study looked at how immune cells, specifically T-cells, change in patients with colitis caused by cancer treatment. Researchers used samples from a patient to identify different types of T-cells throughout the progression of colitis and treatment with pembrolizumab, finding that some T-cells, particularly CD8+ T-cells, were notably reduced during treatment. Understanding these changes can help develop better strategies to manage colitis in cancer patients receiving immune checkpoint inhibitors. Who this helps: Cancer patients undergoing treatment with immune checkpoint inhibitors.

Plain English
This study looked at how immune functions change in patients with renal cell carcinoma (RCC), especially in those with brain metastases. Researchers analyzed 76 primary tumors and 86 metastatic tumors, finding that immune signals in brain metastases were notably lower, which could impact treatment effectiveness. For instance, proteins linked to immune activation showed reduced expression, suggesting that patients with brain metastases may have a different response to therapies compared to those with primary tumors. Who this helps: This benefits patients with renal cell carcinoma, particularly those with brain metastases, by informing potential new treatments.

Plain English
This study looked at a new, noninvasive treatment for patients with knee osteoarthritis to see if it could help them avoid surgery. Out of 237 patients treated, 204 (or 86%) successfully avoided total knee replacement over two years. This is important because it shows that this method can save money for healthcare systems while still providing good care for patients. Who this helps: Patients with knee osteoarthritis who want to avoid surgery.

Plain English
This study looked at LAG3 protein levels in kidney cancer patients, comparing concentrations in primary tumors to those found in metastatic sites, including brain metastases. Researchers discovered that LAG3 levels are generally lower at metastatic sites compared to the primary tumors, particularly in patients with more aggressive disease. Specifically, higher LAG3 levels in metastatic tumors might be linked to better responses to immunotherapy and longer survival. Who this helps: This research benefits kidney cancer patients by potentially improving treatment strategies and outcomes.

Plain English
This study looked at how many internal medicine residents at Montefiore Medical Center in New York City were absent from work due to COVID-19-like illness during the pandemic. Out of 245 residents, 103 (42%) were absent, totaling 875 missed workdays, with a peak of 38 residents (16%) out sick at one time. Over time, the number of residents getting sick decreased significantly, proving that even with ongoing patient exposure, the risk of illness dropped as the pandemic continued. Who this helps: This helps doctors and hospital administrators manage staff health and patient care during infectious disease outbreaks.

Plain English
This study looked at a protein called keratin 17 (K17) in breast cancer to see if it could help predict how well patients would do over time. Researchers found that high levels of K17 were linked to worse survival, particularly in patients with advanced, triple-negative breast cancer, with a significant risk increase (over 3.6 times greater for advanced tumors). This is important because it suggests that measuring K17 could help doctors identify patients who might need more aggressive treatment. Who this helps: Patients with advanced or triple-negative breast cancer benefit from this research.

Plain English
This study looked at how communication styles in Syria differ from those in the United States. Researchers found that Syrian students showed higher levels of empathy and social confirmation, while American students were better at forming friendships and displaying warmth in social situations. This matters because understanding these differences can improve interactions between individuals from these cultures. Who this helps: This helps patients and healthcare providers navigate cultural differences in communication.

Plain English
This study looked at how sexual harassment affects employees' happiness at work and their likelihood to leave or miss work in Pakistan and the United States. The findings showed that workers who experienced sexual harassment had lower job satisfaction, higher chances of wanting to leave their jobs, and took more days off. Specifically, in Pakistan, employees who faced harassment were more dissatisfied and absent compared to those in the US. Who this helps: This benefits employees dealing with workplace harassment, especially women in Pakistan.

Plain English
This study focused on developing new imaging agents that can help detect prostate cancer by targeting a specific protein known as prostate-specific membrane antigen (PSMA). Researchers tested four different agents labeled with a radioactive substance, finding that one agent, called (99m)Tc-MIP-1404, showed the best results, with a high uptake in cancerous tissue and a favorable clearance rate from the body. This research is important because it could lead to better tools for diagnosing prostate cancer and tracking how well treatment is working. Who this helps: Patients with prostate cancer.